diagnost tool
price close busi novemb
orasur domin provid saliva collect
devic genet test leader oral fluid
diagnost rapid point care hiv hcv test
nice beat guid inspir
confid buy dip trim pt
deliv solid beat dialogu investor tonight focus
disappoint guid came us
street spoke manag call length best come
guid sandbag coupl moder growth
larg custom like better job plan order throughout year
market leader mix dtc test pop seq microbiom
growth driver similar experienc believ guid
conserv expect stock would buy dip
recommend buy dip buy-back author
put work mention cash balanc sheet buy trim pt
solid beat rev y/i beat
guid driven beat molecular collect
off-set shortfal hiv test ancestri payment
risk assess test vs model gm impress beat
includ lift ancestrydna royalti payment ep beat
hcv rev basic line
dnag deliv y/i growth dnag
y/i ad new custom saw
either doubl triple-digit growth top custom east/n africa
grew y/i microbiom rev grew y/i
hiv ou hiv ou rev y/i ytd remain brisk
dismiss who/unitaid report forecast
hiv self-test could deploy indic forecast
consist see would suggest big upsid
soft guid truli look conserv initi revenu guid
guid ep
analyst investor alik surpris
given still-robust earli inflect dtc testing/om thu best
come guid sand-bag better job plan
year spread order throughout year stock importantli
littl doubt volum nice y/i thu reason doubt
molecular collect busi meet goal solid double-digit
think could mean y/i
cohort breast cancer studi announc suppli hospit network
collect sampl breast cancer survivor franc new us think
one mani larg cohort studi come mention project like us
genom england believ skin game
hcv erad project may mummifi see page
us next week pleas host ceo steve tang cfo roberto cuca
annual canaccord diagnost forum nyc next thursday
contact canaccord genuiti salesperson detail
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hcv erad may mummifi discuss manag post
call discuss possibl resurrect hcv countrywid erad
project street model zero wise view still
activ dialogu sever countri hcv erad fact manag
indic larg countri renew suppli agreement
still switch hcv test provid fund come
think could possibl win back custom would obvious mark
materi upsid our/street estim view free call option
model lower rev y/i y/i
high end manag guid think
estim conserv think molecular collect could come higher
lower molecular collect revenue estim call y/i
figur think feel conserv us despit difficult growth comp
lower ep high end guid
gross margin gain impress model comment
beat manag indic level
higher result rais gm rais
out-year gm outlook year reiter revenu
estim respect
valuat trim price target price target base
multipl previous revenu estim discount three
year discount rate
buy unchang target price novemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price novemb
diagnost tool
buy unchang target price novemb
diagnost tool
buy unchang target price novemb
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin novemb et
date time product novemb et
price target base multipl revenu estim discount three year discount
pt use multipl adj ep estim
risk achiev target price valuat
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
buy unchang target price novemb
diagnost tool
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
